(S)-2-(Boc-Amino)non-8-Enoic Acid CAS 300831-21-4 Kemurnian >98,0% (GC) ee >99,0% Paritaprevir Intermediate Factory

Katrangan singkat:

Jeneng: (S)-2-(Boc-Amino)non-8-Enoic Acid

CAS: 300831-21-4

Kemurnian:> 98,0% (GC)

ee: > 99,0%

Penampilan: Cairan Coklat

Perantara Paritaprevir (CAS: 1216941-48-8)

E-Mail: alvin@ruifuchem.com

Kirimi email kanggo kita

Detail Produk

Produk sing gegandhengan

Tag produk

katrangan:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Sifat Kimia:

Jeneng Kimia	(S)-2-(Boc-Amino)non-8-Enoic Acid
sinonim	(S)-2-(tert-Butoxycarbonylamino)non-8-Enoic Acid;(S)-2-(Boc-Amino)-8-Asam Nonenoat;(2S)-2-[(2-Methylpropan-2-yl)oxycarbonylamino]non-8-Enoic Acid;(2S)-2-{[(tert-Butoxy)carbonyl]amino}non-8-Enoic Acid
Nomer CAS	300831-21-4
Nomer CAT	RF-CC347
Status Simpenan	Ing Simpenan
Formula Molekul	C14H25NO4
Bobot Molekul	271.35
Kapadhetan	1,035±0,06 g/cm3
Merk	Kimia Ruifu

Spesifikasi:

Item	Spesifikasi
Penampilan	Cairan Coklat
Kemurnian / Metode Analisis	> 98,0% (GC)
ee	> 99.0%
Test Standar	Standar Perusahaan
Panggunaan	Perantara Paritaprevir (CAS: 1216941-48-8)

Paket & Panyimpenan:

Paket: Botol Fluorinated, 25kg / Drum, utawa miturut kabutuhan pelanggan

Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan

Kaluwihan:

FAQ:

Aplikasi:

(S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) bisa digunakake minangka perantara ing sintesis Paritaprevir (CAS: 1216941-48-8) lan analog sing gegandhengan.Paritaprevir minangka inhibitor protease NS3/4A generasi kaping pindho, minangka komponen saka terapi kombinasi virus hepatitis C kabeh-lisan, tanpa interferon sing dikembangake dening Enanta Pharmaceuticals lan AbbVie.Tablet dosis tetep saka Paritaprevir, Ombitasvir lan Ritonavir sing dijupuk bebarengan karo Dasabuvir disetujoni kanggo perawatan genotipe 1 HCV kronis ing AS lan EU ing taun 2014, lan luwih disetujoni kanggo perawatan infeksi HCV kronis genotipe 4 tanpa sirosis dening AS. FDA ing 2015.